Our company has engaged in the research and development of dry powder inhaler since 1994. And we have accumulated extensive experience in formulation, filling, device design, etc. By far we have applied and granted a number of patents both domestic and worldwide. Our products cover the mainstream inhalers in domestic and foreign markets, including capsule-based, disc-based, blister-based, and reservoir-based inhalers. Leveraging the full set of R&D equipment and experienced team, we can provide a range of services, such as design and development of dry powder inhaler, 3D printing, product design, numerical simulation, die sinking and injection, automatic assembly, and assembly line design.
Inhal has a comprehensive expertise in formulation development, and is capable of developing Carrier-free drug formulation and Carrier-based formulation. Carrier-free formulation only contains micronized fine drug particles, which can be used in combination with matching inhaler devices to achieve excellent pulmonary drug delivery. Carrier-based formulation uses large lactose (30-300 μm) as carriers to improve its flowability for easy handing, dispensing and metering of the drug. In most cases, the fine drug particles are attached onto the surface of the large lactose to form an ordered mixture that helps improve bulk property.
Inhal innovatively applies the fluidized bed technology to the quantitative packaging of ultra-fine powder for pure powder without excipients particularly. It uses technologies protected with independent intellectual property rights (China Patent ZL02825232.2), including the rotating fluidized bed, auxiliary fluidization technology, alternate switching of gas distributors, fluidized bed walls and gas discharge ceilings, to obtain uniform and fully fluidized gas-solid suspensions, and pass the gas-solid suspension while maintaining the density and shape of the gas-solid suspensions. The method of constant volume or constant flow rate realizes accurate powder measurement. This innovation keeps the fluidization uniformity of gas-solid suspended matter higher than 95%, quantifies 25-2000 micrograms per does, and keeps the average error below 7.5%.
Suzhou Inhal Pharma Co., Ltd., led by Professor Jingxu Zhu, academician of the Academy of Science of the Royal Society of Canada and Canadian Academy of Engineering, is located in Suzhou Industrial Park. Inhal Pharma is a scientific and technological innovation company specializing in the research and development of inhalation formulation, inhalers, and filling equipment. Inhal is committed to creating a precise drug delivery platform for integrated drug delivery, realizing interconnection with upstream-downstream enterprises, and providing turnkey solution in the field of inhalation drug delivery for global pharmaceutical companies.
Academician Zhu's team has been engaged in inhalation drug delivery research since 1994 and has accumulated more than 20 years’ experience. Inhal has achieved drug screening and evaluation, formulation design and optimization of powder aerosolization, research and development of dry powder inhalation device, precise and quantitative repackaging technology and equipment development of ultrafine powder drugs, and construction of lung targeted drug delivery system.
Suzhou Inhal Pharma Co., Ltd., a leading domestic innovative dry powder inhalation (DPI) company, successfully completed round A financing, raising more than 50-million-yuan RMB (about US $6.8 mn) in funds.
InhalPharma, as the sponsor of 13th CIS-ASIA, released the self-developed Reservoir Type Dry Powder Inhalation device for the first time in the "Inhalation Development" forum.